ARCHIVES

Coulter And Venture Capital Firm Form Company To Develop B1 Antibody For NHL

This article is from The Cancer Letter archive.

Vol. 21 No. 17 | April 28, 1995

Download PDF Visit The Full Archive

Related Articles

Decision Network Votes 14-11 for Laetrile Testing

September 29, 1978

Iressa Just As Effective As Chemotherapy For Second-Line Therapy, Study Finds

November 28, 2008

Vasopermeation Technology Awarded Patent For CA Firm.

September 28, 2001

Funding opportunities listed.

November 5, 2004

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012